Top Markets
Coin of the day
Oscotec Inc. Oscotec Inc.

Oscotec Inc.

039200
株式のランク #9790
Oscotec Inc. is a biopharmaceutical company specializing in the discovery and... Oscotec Inc. is a biopharmaceutical company specializing in the discovery and development of novel therapeutic drugs. Its primary focus lies in advancing a pipeline of investigational medicines, including a SYK inhibitor currently in Phase IIa clinical trials for the treatment of both rheumatoid arthritis and immune thrombocytopenia. Another key asset is an FLT3 inhibitor, undergoing Phase I clinical evaluation for acute myeloid leukemia. The company is also developing an EGFR double mutation inhibitor aimed at non-small cell lung cancer, and an Anti-Tau antibody in the preclinical stage for Alzheimer's disease. Beyond its pharmaceutical endeavors, Oscotec Inc. diversifies its offerings with a range of dental health products, such as bone graft materials like InduCera, BioCera-F, and SynCeraII, alongside membranes including LysoGide and CollaGuide. Additionally, it markets functional ingredients designed to address specific health concerns, such as OPB for osteoporosis, AIF for arthritis, SGA for enhancing bone growth, and PRF-K for periodontal conditions. Established in 1988, the company, originally known as Oscotec Co., Ltd, adopted its current name, Oscotec Inc., in June 1999. It is headquartered in Seongnam, South Korea.
株価
$24.76
最終同期: 2026-08-28
時価総額
$947.10M
変化(1日)
2.14%
変化(1年)
-6.44%
KR
取引 Oscotec Inc. (039200)

カテゴリー

Oscotec Inc.(039200)の利益
2026 時点の利益 TTM: 0
Oscotec Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Oscotec Inc. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差
$33.59B -
US
$25.20B -
US
$8.70B -
US
$21.39B -
CH
$5.95B -
US